Moderna and Merck Announce Positive Phase 2b Trial Results for mRNA Melanoma Vaccine

Moderna and Merck have reported that an investigational mRNA vaccine, in combination with Keytruda, significantly reduced the recurrence of melanoma in a Phase 2b clinical trial. This development could mark a significant step forward in cancer treatment, potentially ushering in a new era of personalized cancer immunotherapies.